Nicox and Re-Vana Therapeutics have entered a research collaboration to study the possibility of combining Nicox’s stand-alone nitric oxide donors with Re-Vana’s EyeLief drug delivery platform for the reduction of IOP, according to a Nicox press release.
Re-Vana will be responsible for developing and characterizing EyeLief implants containing the NO donors and for the initial in vitro evaluations of the implants. The development of the EyeLief platform for sustained release of Nicox’s NO donors will be the focus of the nonexclusive agreement, the release said.
“Re-Vana’s
Uncategorized